Effect of grapefruit juice on bioavailability of montelukast

被引:7
|
作者
Cingi, Cemal [1 ]
Toros, Sema Zer [2 ]
Gurbuz, Melek Kezban [1 ]
Ince, Iskender [3 ]
Cakli, Hamdi [1 ]
Erdogmus, Nagehan [1 ]
Karasulu, Ercument [1 ,3 ]
Kaya, Ercan [3 ]
机构
[1] Osmangazi Univ, Dept Otorhinolaryngol, Fac Med, Eskisehir, Turkey
[2] Haydarpasa Numune Res & Educ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Istanbul, Turkey
[3] Ege Univ, Ctr Drug Res & Dev & Pharmacokinet Applicat, TR-35100 Izmir, Turkey
来源
LARYNGOSCOPE | 2013年 / 123卷 / 04期
关键词
Grapefruit juice; montelukast; allergy; bioavailability; asthma; drug interactions; ALLERGIC RHINITIS; DESLORATADINE; COMBINATION;
D O I
10.1002/lary.23700
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives/Hypothesis: The aim of this study was to investigate possible interactions between grapefruit juice and montelukast for up to 4 hours. Study Design: A prospective, crossover study with 23 healthy volunteers was performed in two sessions. Methods: In the first session, volunteers were treated with oral montelukast 10 mg once daily with 250 ml water. After a 10-day washout period, the same volunteers were treated with 10 mg montelukast with 250 ml grapefruit juice. Blood samples were collected 2, 3, and 4 hours after drug administration and kept at 80 degrees C after both applications. Plasma samples were analyzed for montelukast concentration. Results: The mean plasma concentration of montelukast across all time intervals was significantly greater (P = 0.0001) for those given grapefruit juice (517, 484, and 440) versus those treated with water (366, 356, and 292). Moreover, with respect to the time the sample was collected, there was no significant difference (P = 0.13) in the mean total plasma concentration up to 4 hours after montelukast ingestion for either group. There was a significant difference between the groups according to the area under curve with regard to marginal and cumulative values for all different time intervals (P < 0.05). Conclusions: Plasma concentration of montelukast was higher when administered with grapefruit juice, as compared to with water. This may have been due to the effect of grapefruit on liver metabolism of montelukast and the cytochrome P450 system.
引用
收藏
页码:816 / 819
页数:4
相关论文
共 50 条
  • [1] Effect of grapefruit juice intake on etoposide bioavailability
    Reif, S
    Nicolson, MC
    Bisset, D
    Reid, M
    Kloft, C
    Jaehde, U
    McLeod, HL
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (07) : 491 - 494
  • [2] Effect of grapefruit juice intake on etoposide bioavailability
    Stefanie Reif
    Marianne C. Nicolson
    Donald Bisset
    Muriel Reid
    Charlotte Kloft
    Ulrich Jaehde
    Howard L. McLeod
    European Journal of Clinical Pharmacology, 2002, 58 : 491 - 494
  • [3] Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability
    Nagy, J
    Schipper, HG
    Koopmans, RP
    Butter, JJ
    Van Boxtel, CJ
    Kager, PA
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2002, 66 (03): : 260 - 263
  • [4] Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy
    Garg, SK
    Kumar, N
    Bhargava, VK
    Prabhakar, SK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) : 286 - 288
  • [5] Bioavailability of furocoumarins after ingestion of grapefruit or grapefruit juice
    Lee, Sang Gil
    Kim, Kijoon
    Vance, Terrence
    Perkins, Christopher
    Provatas, Anthony
    Qureshi, Abrar
    Cho, Eunyoung
    Chun, Ock K.
    FASEB JOURNAL, 2015, 29
  • [6] LACK OF EFFECT OF GRAPEFRUIT JUICE ON DILTIAZEM BIOAVAILABILITY IN NORMAL SUBJECTS
    SIGUSCH, H
    HENSCHEL, L
    KRAUL, H
    MERKEL, U
    HOFFMANN, A
    PHARMAZIE, 1994, 49 (09): : 675 - 679
  • [9] Grapefruit juice increases the bioavailability of artemether
    van Agtmael, MA
    Gupta, V
    van der Wösten, TH
    Rutten, JPB
    van Boxtel, CJ
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (05) : 405 - 410
  • [10] Grapefruit juice increases the bioavailability of artemether
    M. A. van Agtmael
    V. Gupta
    T. H. van der Wösten
    J.-P. B. Rutten
    C. J. van Boxtel
    European Journal of Clinical Pharmacology, 1999, 55 : 405 - 410